Jay S. Duker - 09 Feb 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
President and COO
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
09 Feb 2023
Net transactions value
-$17,297
Form type
4
Filing time
13 Feb 2023, 16:03:38 UTC
Previous filing
10 Jan 2023
Next filing
22 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +7,000 +33% $0.000000 28,402 09 Feb 2023 Direct
transaction EYPT Common Stock Options Exercise $0 +4,967 +17% $0.000000 33,369 09 Feb 2023 Direct
transaction EYPT Common Stock Tax liability $10,116 -2,426 -7.3% $4.17 30,943 09 Feb 2023 Direct F1
transaction EYPT Common Stock Tax liability $7,181 -1,722 -5.6% $4.17 29,221 09 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -7,000 -33% $0.000000 14,000 09 Feb 2023 Common Stock 7,000 $0.000000 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -4,967 -50% $0.000000 4,967 09 Feb 2023 Common Stock 4,967 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.
F2 The restricted stock units vests in three annual installments beginning February 9, 2023.
F3 The restricted stock units vests in three ratable annual installments beginning February 9, 2022.